Most importantly, data from this report taken together with other recent work [18] point to a unidirectional pathway whereby JAM-A levels influence FOXA1 and, subsequently, HER2 expression in breast cancer settings (Model, Figure 8). The gene discussed is FOXA1; the disease is breast carcinoma.